Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission
Portfolio Pulse from
Candel Therapeutics Inc (NASDAQ:CADL) is advancing its lead candidate, CAN-2409, targeting prostate cancer towards FDA submission. The company anticipates significant milestones in 2024, with updated survival data from phase 2a trials in PDAC and NSCLC expected in Q1 2025.
January 13, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Candel Therapeutics is advancing its lead candidate CAN-2409 for prostate cancer towards FDA submission, with significant milestones expected in 2024 and updated trial data in 2025.
The advancement of CAN-2409 towards FDA submission is a positive development for Candel Therapeutics, potentially increasing investor interest and stock value. The anticipation of significant milestones in 2024 and updated trial data in 2025 further supports a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100